Alzheimer's disease affects more than 20 million people worldwide. More people will be impacted as the cohort of adults aged 65 and older rises and if disease modifying therapies are not fully approved. Clinical trials for Alzheimer's disease are scientifically and operationally challenging. Sponsors need innovative solutions to drive new therapies to market.
In this webinar, IQVIA experts will share how to harness data, technology, and advanced analytics to inclusively recruit the right patients in the right places at the right time into Alzheimer's disease clinical trials. Learn how to:
Access broad and deep neurology expertise to reduce costs, accelerate timelines and manage risk, from clinical trials to evidence generation and beyond.
Specialized expertise and customized solutions across 14 therapeutic centers of excellence, including oncology, GI/NASH, pediatrics, neurology and rare diseases.
